Prolaris Q&A with Dr. Brawer

dr-brawer-image

In this video series, Dr. Michael Brawer, Medical Director of Myriad’s Urology Business Unit, addresses nine questions often raised by payers and physicians alike. These questions range from, “Why are long-term studies difficult in prostate cancer?” to “What alternative evidence can be used to validate a prognostic test in prostate cancer?” and “Does Prolaris demonstrate clinical utility?” Click the play button to go to the interactive questionnaire. Once there, click on the square corresponding to your specific question. Stop, pause and move forward at your own pace!

View Series

Safely Choose Active Surveillance & Reduce Overspending on Prostate Cancer Care

Physicians use the Prolaris test for men with localized prostate cancer to add precision to their clinical risk assessment. The unique information provided by Prolaris drives optimal treatment decisions, by identifying patients who can safely choose active surveillance and thereby reduce morbidities associated with unneeded interventions. This net reduction in unnecessary therapies produces an overall cost savings to the healthcare system.

More Info

Prolaris: Helping physicians add precision to prostate cancer risk assessment while reducing unnecessary spending

Chris Cisar, Senior Director of National Accounts for Managed Care, reflects on the recent MolDX coverage policy for Prolaris, a prognostic indicator that identifies localized prostate cancer patients who can safely pursue active surveillance as a primary treatment modality.

The Science Behind Prolaris

Dr. Michael Brawer discusses the Prolaris Score™, which provides a direct measure of individual tumor aggressiveness, and the Prolaris test report, which estimates a patient’s 10-year prostate cancer-specific mortality based upon his unique tumor biology.


For more physician- and patient-focused content
Prolaris® Multimedia Library